CD19 and neoplasm: Consistent with ex vivo results, the antigen-matched combination also achieved a significant (CAR + Ctrl VV [n = 4] versus CAR + CD19 VV [n = 5] day 11 tumor volume; p = 0.0051) delay in tumor progression observable as early as 4 days following initiation of therapy (Figure 4C).